Hasan, A, Falkai, P, Wobrock, T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013; 14(1): 2–44.
Harvey, PD, Loewenstein, DA, Czaja, SJ. Hospitalization and psychosis: influences on the course of cognition and everyday functioning in people with schizophrenia. Neurobiol Dis. 2013; 53: 18–25.
Caseiro, O, Pérez-Iglesias, R, Mata, I, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012; 46(8): 1099–1105.
Correll, CU, Manu, P, Olshanskiy, V, Napolitano, B, Kane, JM, Malhotra, AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302(16): 1765–1773.
Kessing, LV, Thomsen, AF, Mogensen, UG, Andersen, PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010; 197(4): 266–271.
Rummel-Kluge, C, Komossa, K, Schwarz, S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010; 123(2–3): 225–233.
Ulcickas Yood, M, Delorenze, GN, Quesenberry, CP Jr, et al. Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC Psychiatry. 2011; 11: 197.
Hasan, A, Falkai, P, Wobrock, T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012; 13(5): 318–378.
Al-Zoairy, R, Ress, C, Tschoner, A, Kaser, S, Ebenbichler, C. The effects of psychotropic drugs on the regulation of glucose metabolism. Curr Diabetes Rev. 2013; 9(5): 362–370.
Tschoner, A, Engl, J, Laimer, M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007; 61(8): 1356–1370.
Daumit, GL, Goff, DC, Meyer, JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008; 105(1–3): 175–187.
Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951–962.
Meltzer, HY, Risinger, R, Nasrallah, HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015; 76(8): 1085–1090.
Nasrallah, HA, Newcomer, JW, Risinger, R, et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. J Clin Psychiatry. 2016; 77(11): 1519–1525.
McEvoy, JP, Risinger, R, Mykhnyak, S, et al. Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of schizophrenia. J Clin Psychiatry. 2017; 78(8): 1103–1109.
Weiden, PJ, Du, Y, Liu, CC, et al. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. CNS Spectr. 2018; 26: 1–7.
Croxtall, JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs. 2012; 26(2): 155–183.
Kane, JM, Sanchez, R, Perry, PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012; 73(5): 617–624.
Peters-Strickland, T, Baker, RA, McQuade, RD, et al. Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. NPJ Schizophr. 2015; 1: 15039.
McEvoy, JP, Lieberman, JA, Perkins, DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007; 164(7): 1050–1060.
Guo, Z, L'Italien, GJ, Jing, Y, et al. A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(5): 1326–1332.
Potkin, SG, Raoufinia, A, Mallikaarjun, S, et al. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin. 2013; 29(10): 1241–1251.
Kane, JM, Peters-Strickland, T, Baker, RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014; 75(11): 1254–1260.
Robinson, DG, Gallego, JA, John, M, et al. A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull. 2015; 41(6): 1227–1236.